The control mortality rates range between 31% and 61%, indicating that the beneficial effects of adjunct therapies could be demonstrated over a wide range of illness severity.
The control group mortality rates for these studies were 31%, 43% and 61%, indicating that the beneficial effects of adjunct therapies could be demonstrated over a wide range of illness severity.
The control group mortality rates for these three studies were 43%, 31%and61%1%, respectively, indicating that the beneficial effects of adjunct therapies could be demonstrated over a wide range of illness severity.
It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux®) which has already been shown to be effective in colorectal as well as head-and-neck tumours with comparatively mild side-effects.
aWNV, West Nile virus; SLEV, St . Louisencephalitis virus; FLAVI, flavivirus; WNV+, samples in which a fourfold difference in WNV antibody titer over SLEV could be demonstrated; SLEV+.
samples in which a fourfold difference in SLEV antibody titer over WNV could be demonstrated; FLAVI+, samples in which a fourfold difference in titer between WNV and SLEV could not be demonstrated and therefore classified as flavivirus positive; CI, confidence interval; NT, not tested for viremia.
In a recent meta-analysis, volumetric deficits at diagnosis were seen in total brain volume, in the hippocampus, in cortical grey matter, in Heschl's gyrus, in the planum temporal and in temporal grey matter, and in longitudinal studies continued volumetric loss over time could be demonstrated in these structures [ 22].
At an average follow-up of 7.1 years, no significant differences of FB over MB design could be demonstrated with respect to the American Knee Society score (AKSS), pain score, a questionnaire of general health (SF-12 score), range of motion (ROM), or complication rates.
A total of 120 evaluable patients was considered to be a sufficient sample size to ensure, with 80%% power and at a 5%% one-sided significance level, that non-inferiority of Gd-DOTA-MRI over unenhanced MRI could be demonstrated with a fixed −15%% non-inferiority margin.
Calcein leaking out of dying cells could be demonstrated by quantifying the percentage of calcein fluorescence over time of the two dying cells (Fig. 2E).
However, a correlation between sCOMP and the delta Larsen score over 5 years in this patient group could be demonstrated.
